Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients
Clinical Science · 15.01.2025 · 139 (1) · 29-41
DOI: 10.1042/cs20241529 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Science, online erschienen am 15.01.2025. Verfasst von Stephen Rankin und 13 weiteren Autor:innen. Beteiligte Einrichtung: BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K. Hauptthemen laut MEDLINE: Doxorubicin, Lymphoma, Large B-Cell, Diffuse, Antibiotics, Antineoplastic, Anthracyclines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, Roche Holding | Roche Diagnostics.
Abstract (Originalsprache)
Anthracyclines, such as doxorubicin, are important anti-cancer therapies but are associated with arterial injury. Histopathological insights have been limited to small animal models, and the role of inflammation in the arterial toxic effects of anthracycline is unclear in humans. Our aims were (1) to evaluate aortic media fibrosis and injury in non-human primates treated with anthracyclines; (2) to assess the effect of anthracycline on aortic inflammation in patients treated for lymphoma. African Green monkeys (AGMs) received doxorubicin (30–60 mg/m2/biweekly intravenously, cumulative dose: 240 mg/m2). Blinded histopathologic analyses of the ascending aorta were performed 15 weeks after the last doxorubicin dose and compared to five age- and gender-matched healthy, untreated AGMs. Analysis of the thoracic aorta of patients with diffuse large B-cell lymphoma (DLBCL), at baseline and after doxorubicin exposure, was performed using 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in this observational study by maximal tissue-to-background ratio (TBRmax). In AGMs, doxorubicin exposure was associated with greater aortic fibrosis (collagen deposition: doxorubicin 6.23 ± 0.88% vs. controls 4.67 ± 0.54%; P=0.01) and intracellular vacuolization (doxorubicin 66.3 ± 10.1 vs. controls 11.5 ± 4.2 vacuoles/field, P<0.0001) than untreated controls. In 101 patients with DLBCL, there was no change in aortic TBRmax after anthracycline exposure (TBRmax 1.46 ± 0.16 vs. 1.44 ± 0.14, respectively, P=0.14). Univariate analyses yielded similar results. In a large animal model, anthracycline exposure was associated with aortic fibrosis. In patients with lymphoma, anthracycline exposure was not associated with aortic inflammation. Further research is required to elucidate the mechanisms of anthracycline-related vascular harm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K.
- Departments of Internal Medicine, Section on Cardiology and Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, U.S.A.
- Department of Clinical Physics & Bioengineering, NHS Greater Glasgow & Clyde, Glasgow.
- School of Medicine, Dentistry and Nursing, University of Glasgow.
- The Beatson West of Scotland Cancer Centre, Glasgow, UK.
- Cedars-Sinai, Division of Artificial Intelligence in Medicine, Department of Medicine, Los Angeles, U.S.A.
ORCID-Profile: Stephen Rankin, Mark C Petrie, Ninian N Lang
Förderung
- NHLBI NIH HHS
- NIH HHS
- Roche Holding | Roche Diagnostics
- BHF Centre of Research Excellence, Oxford
- Merck & Co. | Merck Animal Health
- Vervet Research Colony
- Foundation for the National Institutes of Health
Zitieren
APA
Rankin, S., Fountain, C., Gemmell, A. J., Quinn, D., Henderson, A., McClure, J., Small, S., Venugopal, B., McKay, P., Slomka, P. J., Colville, D., Petrie, M. C., Meléndez, G. C., & Lang, N. N. (2025). Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients. Clinical Science, 139(1), 29-41. https://doi.org/10.1042/cs20241529
Vancouver
Rankin S, Fountain C, Gemmell AJ, Quinn D, Henderson A, McClure J, et al. Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients. Clinical Science. 2025;139(1):29-41. doi:10.1042/cs20241529
BibTeX
@article{Rankin2025,
author = {Rankin, Stephen and Fountain, Caitlin and Gemmell, Alastair J and Quinn, Daire and Henderson, Alasdair and McClure, John and Small, Sandy and Venugopal, Balaji and McKay, Pamela and Slomka, Piotr J and Colville, David and Petrie, Mark C and Meléndez, Giselle C and Lang, Ninian N},
title = {Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients},
journal = {Clinical Science},
year = {2025},
volume = {139},
number = {1},
pages = {29--41},
doi = {10.1042/cs20241529}
}
EUVIMED